Steven St Peter
CIK 1352447 · PRESIDENT AND CEO · last filed 2018-12-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
PETX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
200 CLARENDON STREET 54TH FLOOR
BOSTON, MA 02116
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ARATANA THERAPEUTICS, INC. (PETX) Delisted | PRESIDENT AND CEO | 603,623 | — | — | -$5.86M | 26 | 2018-12-17 |
| Altimmune, Inc. (PIP) Delisted | Director | 18,500 | — | — | $41.2K | 13 | 2017-01-05 |
| Omrix Biopharmaceuticals, Inc. (OMRI) Delisted | Director | 4,000 | — | — | -$81.1K | 3 | 2008-09-05 |
| HELICOS BIOSCIENCES CORP (HLCS) Delisted | Director | — | — | — | $0 | 1 | 2007-07-31 |
Recent Filings · Page 2 of 5
45 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-10-04 | ARATANA THERAPEUTICS, INC. (PETX) Delisted | Sell (S) | −50,000 | -$312.1K | EDGAR |
| 2017-04-18 | ARATANA THERAPEUTICS, INC. (PETX) Delisted | Mixed | −3,334 | -$130.6K | EDGAR |
| 2017-01-31 | ARATANA THERAPEUTICS, INC. (PETX) Delisted | Sell (S) | −50,000 | -$385.9K | EDGAR |
| 2017-01-17 | ARATANA THERAPEUTICS, INC. (PETX) Delisted | Grant (A) | +139,900 | $0 | EDGAR |
| 2017-01-05 | Altimmune, Inc. (PIP) Delisted | Exer (M) | +70,000 | $181.5K | EDGAR |
| 2016-12-16 | ARATANA THERAPEUTICS, INC. (PETX) Delisted | Mixed | −100,000 | -$381.4K | EDGAR |
| 2016-09-20 | Altimmune, Inc. (PIP) Delisted | Exer (M) | +110,004 | $175.9K | EDGAR |
| 2016-08-10 | ARATANA THERAPEUTICS, INC. (PETX) Delisted | Sell (S) | −50,000 | -$462.5K | EDGAR |
| 2016-06-17 | ARATANA THERAPEUTICS, INC. (PETX) Delisted | Sell (S) | −100,000 | -$626.3K | EDGAR |
| 2016-06-03 | Altimmune, Inc. (PIP) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.